Difference between revisions of "Team:Oxford"
| (10 intermediate revisions by 2 users not shown) | |||
| Line 34: | Line 34: | ||
<div class="row"> | <div class="row"> | ||
<div class=".col-md-8 .offset-md-2"> | <div class=".col-md-8 .offset-md-2"> | ||
| + | |||
| + | <style type="text/css"> | ||
| + | .tftable {font-size:17px;color:#333333;width:100%;border-width: 1px;border-color: #729ea5;border-collapse: collapse;} | ||
| + | .tftable th {font-size:17px;background-color:#E5FCE2;border-width: 1px;padding: 8px;border-style: solid;border-color: #729ea5;text-align:left;text-align:center;} | ||
| + | .tftable tr {background-color:#FFFFFF;} | ||
| + | .tftable td {font-size:17px;border-width: 1px;padding: 8px;border-style: solid;border-color: #729ea5; text-align:center;} | ||
| + | .tftable tr:hover {background-color:#F2F2F2;} | ||
| + | h3 { | ||
| + | text-decoration:; | ||
| + | } | ||
| + | </style> | ||
| + | |||
| + | <table class="tftable" border="1"> | ||
| + | <center> | ||
| + | <tr><th>Achievement</th><th>Award</th></tr> | ||
| + | <tr><td>Winners</td><td>Therapeutics Track</td></tr> | ||
| + | <tr><td>Nominated</td><td>Best Human Practices</td></tr> | ||
| + | <tr><td>Nominated</td><td>Best Entrepreneurship</td></tr> | ||
| + | </td><td>Nominated</td><td>Best Wiki</td></tr> | ||
| + | </td><td>Gold</td><td>Medal</td></tr> | ||
| + | </center></table> | ||
| + | <br> | ||
| + | |||
<h2>Abstract<br></h2> | <h2>Abstract<br></h2> | ||
<p class="lead"><br>Inflammatory Bowel Disease (IBD) is characterised by chronic inflammation of the intestine. The condition is associated with an imbalance in immune cell populations, notably Th17 and Treg. Existing immunosuppressive therapies, when successful, often elicit systemic side effects and require frequent readministration. Our solution is to develop a probiotic strain that restores the Th17/Treg cell balance via secretion of IL-10 in response to nitric oxide in the intestinal lumen. Overshoot is prevented by an adenine riboswitch-sRNA construct which responds to extracellular adenosine, an indicator of the Treg cell population. Integration of separate stimuli in a dual feedback loop enables a more dynamic, robust response to the immune state of the body. Various features have been incorporated to maximise biological safety, including an inducible kill switch system. We believe our design offers a non-invasive, self-tuning therapeutic for IBD, with potential to replace conventional immunosuppressants in the treatment of gastrointestinal autoimmune disorders. </p> | <p class="lead"><br>Inflammatory Bowel Disease (IBD) is characterised by chronic inflammation of the intestine. The condition is associated with an imbalance in immune cell populations, notably Th17 and Treg. Existing immunosuppressive therapies, when successful, often elicit systemic side effects and require frequent readministration. Our solution is to develop a probiotic strain that restores the Th17/Treg cell balance via secretion of IL-10 in response to nitric oxide in the intestinal lumen. Overshoot is prevented by an adenine riboswitch-sRNA construct which responds to extracellular adenosine, an indicator of the Treg cell population. Integration of separate stimuli in a dual feedback loop enables a more dynamic, robust response to the immune state of the body. Various features have been incorporated to maximise biological safety, including an inducible kill switch system. We believe our design offers a non-invasive, self-tuning therapeutic for IBD, with potential to replace conventional immunosuppressants in the treatment of gastrointestinal autoimmune disorders. </p> | ||
| Line 47: | Line 70: | ||
<div class="service-section-03 tiles-wrapper"> | <div class="service-section-03 tiles-wrapper"> | ||
| − | <div class="col-md-3 | + | <div class="col-md-3"> |
<a href="https://2018.igem.org/Team:Oxford/Description"> | <a href="https://2018.igem.org/Team:Oxford/Description"> | ||
<div class="team-style-01 text-center section-block-p tile"> | <div class="team-style-01 text-center section-block-p tile"> | ||
| Line 59: | Line 82: | ||
</a> | </a> | ||
</div> | </div> | ||
| − | <div class="col-md-3 | + | <div class="col-md-3"> |
<a href="https://2018.igem.org/Team:Oxford/Our_solution"> | <a href="https://2018.igem.org/Team:Oxford/Our_solution"> | ||
<div class="team-style-01 text-center section-block-p tile"> | <div class="team-style-01 text-center section-block-p tile"> | ||
| Line 71: | Line 94: | ||
</a> | </a> | ||
</div> | </div> | ||
| − | <div class="col-md-3 | + | <div class="col-md-3"> |
<a href="https://2018.igem.org/Team:Oxford/Parts"> | <a href="https://2018.igem.org/Team:Oxford/Parts"> | ||
<div class="team-style-01 text-center section-block-p tile"> | <div class="team-style-01 text-center section-block-p tile"> | ||
| Line 83: | Line 106: | ||
</a> | </a> | ||
</div> | </div> | ||
| − | <div class="col-md-3 | + | <div class="col-md-3"> |
<a href="https://2018.igem.org/Team:Oxford/wetlab"> | <a href="https://2018.igem.org/Team:Oxford/wetlab"> | ||
<div class="team-style-01 text-center section-block-p tile"> | <div class="team-style-01 text-center section-block-p tile"> | ||
| Line 95: | Line 118: | ||
</a> | </a> | ||
</div> | </div> | ||
| − | <div class="col-md-3 | + | <div class="col-md-3"> |
<a href="https://2018.igem.org/Team:Oxford/Model"> | <a href="https://2018.igem.org/Team:Oxford/Model"> | ||
<div class="team-style-01 text-center section-block-p tile"> | <div class="team-style-01 text-center section-block-p tile"> | ||
| Line 107: | Line 130: | ||
</a> | </a> | ||
</div> | </div> | ||
| − | <div class="col-md-3 | + | <div class="col-md-3"> |
<a href="https://2018.igem.org/Team:Oxford/Entrepreneurship"> | <a href="https://2018.igem.org/Team:Oxford/Entrepreneurship"> | ||
<div class="team-style-01 text-center section-block-p tile"> | <div class="team-style-01 text-center section-block-p tile"> | ||
| Line 119: | Line 142: | ||
</a> | </a> | ||
</div> | </div> | ||
| − | <div class="col-md-3 | + | <div class="col-md-3"> |
<a href="https://2018.igem.org/Team:Oxford/Applied_Design"> | <a href="https://2018.igem.org/Team:Oxford/Applied_Design"> | ||
<div class="team-style-01 text-center section-block-p tile"> | <div class="team-style-01 text-center section-block-p tile"> | ||
| Line 131: | Line 154: | ||
</a> | </a> | ||
</div> | </div> | ||
| − | <div class="col-md-3 | + | <div class="col-md-3"> |
<a href="https://2018.igem.org/Team:Oxford/Engagement"> | <a href="https://2018.igem.org/Team:Oxford/Engagement"> | ||
<div class="team-style-01 text-center section-block-p tile"> | <div class="team-style-01 text-center section-block-p tile"> | ||
Latest revision as of 03:02, 8 December 2018
Revolutionising Immunosuppressants
| Achievement | Award |
|---|---|
| Winners | Therapeutics Track |
| Nominated | Best Human Practices |
| Nominated | Best Entrepreneurship | Nominated | Best Wiki | Gold | Medal |
Abstract
Inflammatory Bowel Disease (IBD) is characterised by chronic inflammation of the intestine. The condition is associated with an imbalance in immune cell populations, notably Th17 and Treg. Existing immunosuppressive therapies, when successful, often elicit systemic side effects and require frequent readministration. Our solution is to develop a probiotic strain that restores the Th17/Treg cell balance via secretion of IL-10 in response to nitric oxide in the intestinal lumen. Overshoot is prevented by an adenine riboswitch-sRNA construct which responds to extracellular adenosine, an indicator of the Treg cell population. Integration of separate stimuli in a dual feedback loop enables a more dynamic, robust response to the immune state of the body. Various features have been incorporated to maximise biological safety, including an inducible kill switch system. We believe our design offers a non-invasive, self-tuning therapeutic for IBD, with potential to replace conventional immunosuppressants in the treatment of gastrointestinal autoimmune disorders.